PURPOSE OF REVIEW: This review summarizes the background and implementation of the Fistula First Breakthrough Initiative (FFBI), published information about changes in vascular access practice since its inception, and several issues raised by the program. RECENT FINDINGS: The FFBI is a surveillance system using the End-Stage Renal Disease (ESRD) Networks to spread improvement ideas. Concomitant with implementation of the program, prevalent arteriovenous fistula use has increased an average of 3.3% annually since 2003, an incremental improvement of 1.3% over the preexisting trend. At the same time, long-term central venous catheter (CVC) use declined among the prevalent population. Increasingly, individual facilities are achieving the FFBI goal of 66% prevalent arteriovenous fistula use; however, results vary across geographic regions and are not explained by patient demographic and clinical characteristics alone. SUMMARY: ESRD Network interventions as a function of the FFBI are associated with increasing arteriovenous fistula use and likely contributed to improvement, but improvement cannot be unequivocally attributed to the Networks due to lack of rigorous research design. Questions and opportunities remain. It is not yet clear how to identify patients who may not be appropriate candidates for an arteriovenous fistula. The ultimate impact of the FFBI on patient mortality is yet to be determined. The FFBI must continue to identify variations in use and the contributing causes, and implement strategies to address these causes if the FFBI goal is to be fully achieved.
PURPOSE OF REVIEW: This review summarizes the background and implementation of the Fistula First Breakthrough Initiative (FFBI), published information about changes in vascular access practice since its inception, and several issues raised by the program. RECENT FINDINGS: The FFBI is a surveillance system using the End-Stage Renal Disease (ESRD) Networks to spread improvement ideas. Concomitant with implementation of the program, prevalent arteriovenous fistula use has increased an average of 3.3% annually since 2003, an incremental improvement of 1.3% over the preexisting trend. At the same time, long-term central venous catheter (CVC) use declined among the prevalent population. Increasingly, individual facilities are achieving the FFBI goal of 66% prevalent arteriovenous fistula use; however, results vary across geographic regions and are not explained by patient demographic and clinical characteristics alone. SUMMARY:ESRD Network interventions as a function of the FFBI are associated with increasing arteriovenous fistula use and likely contributed to improvement, but improvement cannot be unequivocally attributed to the Networks due to lack of rigorous research design. Questions and opportunities remain. It is not yet clear how to identify patients who may not be appropriate candidates for an arteriovenous fistula. The ultimate impact of the FFBI on patient mortality is yet to be determined. The FFBI must continue to identify variations in use and the contributing causes, and implement strategies to address these causes if the FFBI goal is to be fully achieved.
Authors: Laura C Plantinga; Cristina Drenkard; Rachel E Patzer; Mitchel Klein; Michael R Kramer; Stephen Pastan; S Sam Lim; William M McClellan Journal: Arthritis Rheumatol Date: 2015-03 Impact factor: 10.995
Authors: Laura C Plantinga; Min Kim; Margarethe Goetz; David G Kleinbaum; William McClellan; Rachel E Patzer Journal: Am J Nephrol Date: 2014-01-15 Impact factor: 3.754
Authors: Laura C Plantinga; Rachel E Patzer; Cristina Drenkard; Stephen O Pastan; Jason Cobb; William McClellan; Sung Sam Lim Journal: BMC Nephrol Date: 2015-03-29 Impact factor: 2.388
Authors: Khalid Bashar; Donagh A Healy; Sawsan Elsheikh; Leonard D Browne; Michael T Walsh; Mary Clarke-Moloney; Paul E Burke; Eamon G Kavanagh; Stewart R Walsh Journal: PLoS One Date: 2015-03-09 Impact factor: 3.240
Authors: Rachel E Patzer; Kayla Smith; Mohua Basu; Jennifer Gander; Sumit Mohan; Cam Escoffery; Laura Plantinga; Taylor Melanson; Sean Kalloo; Gary Green; Alex Berlin; Gary Renville; Teri Browne; Nicole Turgeon; Susan Caponi; Rebecca Zhang; Stephen Pastan Journal: Kidney Int Rep Date: 2017-02-09
Authors: Rebecca Sorber; Joseph K Canner; Christopher J Abularrage; Paula K Shireman; Dorry L Segev; James H Black Iii; Karen Woo; Caitlin W Hicks Journal: Ann Vasc Surg Date: 2021-06-18 Impact factor: 1.607